Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

PubWeight™: 6.08‹?› | Rank: Top 1%

🔗 View Article (PMC 2394854)

Published in Immunity on May 08, 2008

Authors

Qizhi Tang1, Jason Y Adams, Cristina Penaranda, Kristin Melli, Eliane Piaggio, Evridiki Sgouroudis, Ciriaco A Piccirillo, Benoit L Salomon, Jeffrey A Bluestone

Author Affiliations

1: Department of Surgery, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143-0540, USA.

Associated clinical trials:

T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT) | NCT02772679

Articles citing this

(truncated to the top 100)

Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 9.71

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65

The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99

Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16

Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity (2009) 4.85

The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97

In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med (2009) 3.78

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol (2010) 3.69

Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 3.27

Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54

Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol (2011) 2.44

GATA3 controls Foxp3⁺ regulatory T cell fate during inflammation in mice. J Clin Invest (2011) 2.43

Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41

The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol (2008) 2.39

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39

Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol (2010) 2.21

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21

Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med (2015) 2.13

Continuous requirement for the TCR in regulatory T cell function. Nat Immunol (2014) 2.11

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00

Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2009) 1.88

The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A (2008) 1.85

CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med (2013) 1.83

Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol (2009) 1.79

CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol (2011) 1.76

The functional plasticity of T cell subsets. Nat Rev Immunol (2009) 1.74

A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity (2009) 1.72

Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol (2010) 1.72

From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol (2012) 1.70

T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev (2011) 1.69

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63

OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med (2010) 1.62

Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol (2010) 1.58

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity (2015) 1.57

STIM1 and STIM2 protein deficiency in T lymphocytes underlies development of the exocrine gland autoimmune disease, Sjogren's syndrome. Proc Natl Acad Sci U S A (2012) 1.55

IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54

Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes (2009) 1.53

Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy (2009) 1.53

Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med (2013) 1.53

Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest (2010) 1.50

CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A (2011) 1.47

Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40

Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes (2011) 1.39

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A (2009) 1.38

Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38

Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression. PLoS One (2016) 1.38

SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-{gamma} and IL-17A production. J Exp Med (2011) 1.32

Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol (2011) 1.28

Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice. J Exp Med (2011) 1.27

Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J Immunol (2008) 1.27

Once a Treg, always a Treg? Immunol Rev (2014) 1.27

Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27

Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26

Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One (2012) 1.26

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25

CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes (2009) 1.24

An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun (2010) 1.22

Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse. PLoS One (2013) 1.21

The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice. J Clin Immunol (2008) 1.19

Central role for interleukin-2 in type 1 diabetes. Diabetes (2012) 1.19

Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One (2009) 1.19

Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J Immunol (2009) 1.18

Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes (2009) 1.18

Treating human autoimmunity: current practice and future prospects. Sci Transl Med (2012) 1.16

Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One (2009) 1.16

Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol (2011) 1.16

Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. Semin Immunopathol (2010) 1.15

Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol (2016) 1.15

Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses. Front Immunol (2012) 1.14

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest (2014) 1.13

Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies. Diabetes (2009) 1.13

Entry of diabetogenic T cells into islets induces changes that lead to amplification of the cellular response. Proc Natl Acad Sci U S A (2011) 1.13

PTPN22 alters the development of regulatory T cells in the thymus. J Immunol (2012) 1.13

Organ-specific and memory treg cells: specificity, development, function, and maintenance. Front Immunol (2014) 1.11

Application of IL-2 therapy to target T regulatory cell function. Trends Immunol (2012) 1.11

Expression of diabetes-associated genes by dendritic cells and CD4 T cells drives the loss of tolerance in nonobese diabetic mice. J Immunol (2009) 1.10

Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res (2015) 1.09

Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc Natl Acad Sci U S A (2009) 1.09

Mouse Models for Type 1 Diabetes. Drug Discov Today Dis Models (2009) 1.09

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother (2009) 1.08

T cell tolerance and immunity to commensal bacteria. Curr Opin Immunol (2012) 1.06

Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis (2010) 1.04

Translational mini-review series on Th17 cells: CD4 T helper cells: functional plasticity and differential sensitivity to regulatory T cell-mediated regulation. Clin Exp Immunol (2009) 1.04

The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol (2010) 1.03

A cluster of coregulated genes determines TGF-beta-induced regulatory T-cell (Treg) dysfunction in NOD mice. Proc Natl Acad Sci U S A (2011) 1.03

Interindividual variation in human T regulatory cells. Proc Natl Acad Sci U S A (2014) 1.01

Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00

Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes (2010) 1.00

Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. J Med Chem (2011) 1.00

Control of Regulatory T Cell Migration, Function, and Homeostasis. J Immunol (2015) 1.00

Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One (2012) 0.99

Quorum-Sensing in CD4(+) T Cell Homeostasis: A Hypothesis and a Model. Front Immunol (2012) 0.99

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood (2014) 0.97

Articles cited by this

Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature (2002) 11.79

A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48

HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature (1987) 10.70

Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 10.24

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87

Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med (2007) 7.73

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44

Structure and expression of a cloned cDNA for human interleukin-2. Nature (1983) 7.04

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94

The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71

Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 6.38

Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice. Science (1987) 6.36

Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell (1993) 5.99

Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet (2007) 5.68

Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature (2005) 5.39

Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med (2004) 5.08

Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu (1980) 5.03

Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest (2002) 4.73

Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes (2005) 4.34

Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol (2005) 4.09

Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med (2002) 3.94

Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70

Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med (2001) 3.56

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01

Autoimmunity in human primary immunodeficiency diseases. Blood (2002) 3.00

Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med (2003) 2.94

Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes (2005) 2.63

Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med (2005) 2.61

Regulatory T cells in virus infections. Immunol Rev (2006) 2.54

Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell (1995) 2.52

Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol (2003) 2.32

Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis (2006) 2.20

Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13

Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes (2005) 2.10

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am (2000) 2.06

Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med (2005) 2.05

CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun (2005) 1.96

Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics (2003) 1.91

Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev (2006) 1.88

Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes (2002) 1.83

Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med (2007) 1.83

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74

Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity (2001) 1.72

Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66

Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A (2001) 1.62

Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes (2002) 1.61

Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev (2006) 1.58

Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev (1995) 1.58

The tumor-draining lymph node as an immune-privileged site. Immunol Rev (2006) 1.57

A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res (2001) 1.49

Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes (1997) 1.13

The role of regulatory T cells in alloantigen tolerance. Immunol Rev (2006) 1.08

Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T cells to apoptosis induction. Eur J Immunol (1994) 1.06

CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp (2003) 0.99

BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J Autoimmun (1997) 0.98

Overexpression of bcl-2 in T cells affects insulitis in the nonobese diabetic mouse. Scand J Immunol (2003) 0.86

Articles by these authors

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33

Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature (2002) 11.79

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65

CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95

The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94

Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68

Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol (2004) 4.62

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes (2005) 4.19

Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03

Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40

Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med (2006) 3.22

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18

A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07

CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04

Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol (2004) 2.99

Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86

Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest (2003) 2.85

NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68

Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54

The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol (2010) 2.53

Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52

The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol (2004) 2.50

Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39

T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A (2003) 2.34

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30

Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes (2007) 2.27

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21

Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13

Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13

Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol (2012) 2.12

CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02

Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med (2008) 2.01

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90

CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med (2006) 1.88

Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes (2013) 1.79

Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75

How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74

Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73

Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat (2005) 1.72

Murine pancreatic islet isolation. J Vis Exp (2007) 1.68

Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67

Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67

A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65

Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. Blood (2010) 1.63

Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63

Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61

Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55

IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54

The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50

Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49

Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. Proc Natl Acad Sci U S A (2006) 1.47

TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol (2005) 1.46

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45

Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42

Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res (2011) 1.39

Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38

Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33

Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29

Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28

Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27

The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26

Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26

Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One (2012) 1.26